Linked Life Data

10472089

Source:http://linkedlifedata.com/resource/pubmed/id/10472089

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
1999-10-21
pubmed:abstractText
Clinical PET is now primarily used in oncological indications. Fluorine-18-fluorodeoxyglucose (FDG) shows a high uptake in a variety of malignancies and accounts for approximately 95% of the oncological PET studies. The first part of this review deals with theoretical and methodological aspects of FDG-PET. Possible sources of errors for the method are discussed briefly. Oncological indications for FDG-PET are highlighted according to the results of consensus meetings of experts from nuclear medicine and oncology, organized by the German Society of Nuclear Medicine. FDG-PET is mainly used in staging and restaging, demonstrating of tumour recurrence and therapy control. Main benefits of the method are functional imaging, better spatial resolution than conventional scintigraphy and the possibility to perform whole-body imaging easily. A brief outlook on future prospects for the application of PET in oncology is given.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0033-832X
pubmed:author
pubmed:issnType
Print
pubmed:volume
39
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
600-9
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
[FDG-PET in oncology. Methodological principles and clinical applications].
pubmed:affiliation
Klinik für Nuklearmedizin, Universität Wien.
pubmed:publicationType
Journal Article, English Abstract, Review